PRESS PACK

EHDN Clinical Research Congress 2026

Kraków, Poland: 22–24 October 2026

Key facts

Event	EHDN Clinical Research Congress 2026
Dates	22–24 October 2026
Venue	ICE Kraków Congress Centre, Kraków, Poland
Organiser	European Huntington's Disease Network (EHDN)
Focus	Huntington's disease (HD) research, with emphasis on ongoing and upcoming clinical trials alongside the latest scientific advances.
Audience	Clinicians, scientists, advocates, individuals and families impacted by HD
Follows on from	EHDN & Enroll-HD 2024 in Strasbourg
Media contact	krakow2026@ehdn.org / catherine.deeprose@ehdn.org

About the congress

The EHDN Clinical Research Congress 2026 brings together clinicians, scientists, industry partners, advocates, individuals and families from across the HD community. The 2026 edition, held in Kraków, continues the momentum of EHDN & Enroll-HD 2024 in Strasbourg, with a programme centred on clinical development in HD.

The congress programme includes:

- A keynote from Nobel laureate Aaron Ciechanover on ubiquitin proteolytic systems
- Plenary sessions on the patient and family experience of HD and the therapeutic pipeline
- Parallel scientific sessions on clinical trial design, digital biomarkers and AI, genetic modifiers, and social cognition
- Clinical trial updates, including from Alnylam, Vico Therapeutics and Skyhawk Therapeutics
- A poster exhibition and art exhibition, with poster awards on the final day
- Networking events throughout the congress

About EHDN

The European Huntington's Disease Network (EHDN; https://ehdn.org/) is an independent, non-profit organisation dedicated to advancing research, facilitating

clinical trials, and improving care to enhance the quality of life for people impacted by HD.

EHDN advances HD science through the open sharing of data, the provision of research infrastructure and support, the award of seed and strategic funding, and the facilitation of working groups and task forces. It works closely with academic and industrial collaborators to support the development of effective treatment interventions, endorsing studies assessed as meeting high scientific and ethical standards.

EHDN provides a unique combination of expertise, a network of HD clinical sites across Europe, and access to global databases of individuals impacted by HD, including Enroll-HD and REGISTRY (a predecessor to Enroll-HD). Together, these resources support participant recruitment into clinical trials.

EHDN has more than 4,500 members, including clinicians, scientists, and people impacted by HD, spanning over 90 countries, supported by an elected Executive Committee and a central coordination team.

Media information

- This press pack is provided as background for reporting on the event
- Interview requests with EHDN spokespeople can be arranged by contacting us via email
- EHDN and congress logos, and approved photography, are available on request
- Follow and share on social media using #EHDNCRC26 and via EHDN's LinkedIn page
- Contact krakow2026@ehdn.org / catherine.deeprose@ehdn.org (Communications Manager)